Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 1-9    DOI: 10.31083/j.ejgo.2021.01.2251
Special Issue: BRCA and ovarian cancer
Review | Next articles
New treatment strategy for ovarian cancer with a BRCA gene mutation
Tadahiro Shoji1, *(), Kotoka Kikuchi1, Hayato Kogita1, Nanako Jonai1, Hidetoshi Tomabechi1, Akiko Kudoh1, Eriko Takatori1, Takayuki Nagasawa1, Masahiro Kagabu1, Tsukasa Baba1
1Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 028-3695 Yahaba, Japan
Download:  PDF(335KB)  ( 230 ) Full text   ( 64 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Mutated BRCA1/2 genes have been identified as causative genes for ovarian cancer, and it has been reported that 10–20% of all epithelial ovarian cancers have a BRCA mutation. As novel treatment drugs utilizing this BRCA gene mutation, significant attention has been paid to adenine dinucleotide poly (ADP-ribose) polymerase inhibitors. Among them, olaparib has been reported to be useful in patients with a BRCA mutation in Study 19 and SOLO-2 trials. It is important to establish a system for genetic counseling and to perform BRCA gene testing in patients with ovarian cancer. For patients with BRCA -mutated advanced cancer, if adequate response to chemotherapy has been achieved, olaparib is recommended as maintenance therapy for both advanced and recurrent cases. For patients without BRCA gene mutation, bevacizumab combined with chemotherapy or as maintenance therapy is also an option.
Key words:  Ovarian cancer      BRCA mutation      PARP inhibitor     
Submitted:  22 September 2020      Revised:  20 November 2020      Accepted:  04 December 2020      Published:  15 February 2021     
*Corresponding Author(s):  Tadahiro Shoji     E-mail:  tshoji@iwate-med.ac.jp

Cite this article: 

Tadahiro Shoji, Kotoka Kikuchi, Hayato Kogita, Nanako Jonai, Hidetoshi Tomabechi, Akiko Kudoh, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba. New treatment strategy for ovarian cancer with a BRCA gene mutation. European Journal of Gynaecological Oncology, 2021, 42(1): 1-9.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2251     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/1

[1] Sigit Purbadi, Kade Yudi Saspriyana. Primary debulking surgery of advanced epithelial ovarian cancer in developing countries: challenges and expectations[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 26-29.
[2] Ece Gumusoglu, Tuba Gunel, Mohammad Kazem Hosseini, Nogayhan Seymen, Taylan Senol, Uğur Sezerman, Samet Topuz, Kılıç Aydınlı. The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 66-72.
[3] Min Jong Song, Suk Il Jang, Hyon Jee Yoon, Eun Young Ki, Joon Mo Lee, Soo Young Hur. Classical HLA class I antigen downregulation and abnormal HLA-G expression in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 129-138.
[4] Joseph J. Noh, Kyue-Hee Choi, Hyun-Soo Kim, Jeong-Won Lee. Port site implantation of clear cell carcinoma after laparoscopic ovarian cystectomy[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 174-178.
[5] Francesco Plotti, Bartolone Martina, Terranova Corrado, Luvero Daniela, Scaletta Giuseppe, Gatti Alessandra, Benedetti Panici Pierluigi, Angioli Roberto. Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic review of literature[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 889-896.
[6] Irina Esteves-Krasteva, José Ángel Minguez, José María Aramendía, Marta Santisteban, Fernando Martinez-Regueira, Gabriel Zozaya-Larequi, Juan Luis Alcázar, Matías Jurado. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 906-912.
[7] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[8] Haci Ozturk Sahin, Zelal Aydin, Ibrahim Ugras Toktas, Cetin Toraman, Ilkbal Temel Yuksel, Alper Seyhan, Ozgur Akbayir. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 924-930.
[9] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta, Miwa Yasaka, Hiroko Machida, Masae Ikeda, Masako Shida, Takeshi Hirasawa, Mikio Mikami. Usefulness of laparoscopic restaging surgery for patients diagnosed with apparent early ovarian/fallopian tubal cancer by a prior surgery, a case control observational study in a single institute in Japan[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 960-968.
[10] Fatih Kose, Songül Alemdaroğlu, Hüseyin Mertsoylu, Ali Ayberk Beşen, Ozan Cem Güler, Seda Yüksel Şimşek, Gürcan Erbay, Cem Önal, Hüsnü Çelik. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 989-995.
[11] R van de Vrie, E van Werkhoven, M J Rutten, J D Asseler, H S van Meurs, D E Werter, M R Buist, A.H. Zwinderman, C A R Lok, P.M.M. Bossuyt, G G Kenter, P Tajik. Validation of a treatment-selection rule for patients with advanced stage ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 1023-1030.
[12] Buse Güler, Merve Çamlıbel, Samiye Mete. What Do Relatives of Turkish Women with Ovarian Cancer Share on Websites? : A Qualitative Research[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 732-738.
[13] Ji Geun Yoo, Hae Nam Lee, Sung Jong Lee, Jin Hwi Kim, Yong Seok Lee, Ahwon Lee, Soo Young Hur, Keun Ho Lee. Germline BRCA2 mutation is associated with greater progression-free survival in korean women with advanced high-grade serous ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 675-680.
[14] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[15] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
No Suggested Reading articles found!